Wire Stories
Alentis Therapeutics Reports Positive Topline Results From Phase 1 Multiple-ascending Dose Cohorts Study
The trial confirms ALE.F02�s good safety profile, exposure and target biological activity BASEL, Switzerland–(BUSINESS WIRE)–Alentis Therapeutics (�Alentis�), the clinical-stage biotechnology company developing...